IRB #

IRB00008070

Title

E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma

Principal Investigator

John Vetto

Study Purpose

The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better.

Medical Condition(s)

Melanoma, skin

Eligibility Criteria

*Subjects must be 18 years of age or older.
*All subjects must have disease that is completely surgically resected.
* All subjects must be deemed disease free at the time of study entry.

Age Range

18 - 99

Healthy Volunteers Needed

Yes

Duration of Participation

Up to 15 years

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

ECOG

Recruitment End

Compensation Provided

No